Barr challenges Sanofi's Ambien CR insomnia drug
Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables.
Barr challenges Sanofi's Ambien CR insomnia drug

Insomnia :: Barr challenges Sanofi's Ambien CR insomnia drug
Barr Pharmaceuticals, Inc. confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a patent challenge for Sanofi-Aventis U.S. LLC's Ambien CR(R) (Zolpidem Tartrate Extended-Release Tablets), 6.25mg & 12.5mg.
Barr filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Ambien CR product with the U.S. Food & Drug Administration (FDA) in December 2006, and received notification of the application's acceptance for filing in February 2007.
Following receipt of the notice from the FDA, Barr notified Sanofi-Aventis, the New Drug Application (NDA) and patent owner.
On April 5, 2007, Sanofi-Aventis filed suit in the U.S. District Court of New Jersey to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.
Ambien CR (Zolpidem Tartrate Extended-Release Tablets) 6.25mg & 12.5mg is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The product had sales of approximately $659 million in the U.S., based on IMS sales data for the twelve months ended February 2007.
(
Insomnia :: Barr challenges Sanofi's Ambien CR insomnia drug published at
SpiritIndia on Monday, April 9, 2007)
Search more information on
InsomniaRecently posted related articles on Insomnia :
- Insomnia :: GSK & Sepracor announce international alliance for commercilisation of Lunivia
- Insomnia :: Many insomniacs turn to valerian and melatonin to help them sleep
- Insomnia :: Study demonstrated ROZEREM (ramelteon) does not affect body sway
- Insomnia :: CBT workshops an effective means for getting men to seek help for their insomnia
- Insomnia :: Insomniacs pay higher health-care costs than noninsomniacs
- Insomnia :: Night owls report more insomnia-related symptoms
- Insomnia :: Barr challenges Sanofi's Ambien CR insomnia drug
- Brain :: Insomnia drug can improve brain function
- Insomnia :: Treating insomnia is far less costly than ignoring it
- Insomnia :: Insomnia drug prompts strange behaviour
»»
Heart Attack :: Doctors aggressively treat early heart attacks««
Esophageal Cancer :: Cryotherapy to treat cancerous and precancerous conditions of the esophagusThe information provided on
SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information.
Health,
Business,
Science,
Sports,
Entertainment,
Technology
©2002-2009 SpiritIndia.com